UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Expanded carrier screening in pregnant women and women planning pregnancy

Author
Britton D Rink, MD, MS
Section Editor
Louise Wilkins-Haug, MD, PhD
Deputy Editor
Vanessa A Barss, MD, FACOG

INTRODUCTION

Historically, the approach to preconception and prenatal carrier screening has been selective (ie, targeted or condition-directed), based primarily on race/ethnicity and personal/family history. Increasingly, however, patients are asking for and being offered a broader approach to carrier screening, which is possible because of rapid advancements in genetic testing technologies and decreasing costs. Although the information from expanded carrier screening can inform patient and provider decision-making, it can also present practical and ethical challenges that need to be considered.

This topic will discuss issues related to expanded carrier screening in women planning pregnancy or who are pregnant. Genetic screening in specific populations and for specific conditions are reviewed separately:

(See "Carrier screening for genetic disease in the Ashkenazi Jewish population".)

(See "Down syndrome: Overview of prenatal screening".)

(See "Prenatal screening and diagnosis for fragile X syndrome".)

                  
To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Oct 27, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Haque IS, Lazarin GA, Kang HP, et al. Modeled Fetal Risk of Genetic Diseases Identified by Expanded Carrier Screening. JAMA 2016; 316:734.
  2. Shafer FE, Lorey F, Cunningham GC, et al. Newborn screening for sickle cell disease: 4 years of experience from California's newborn screening program. J Pediatr Hematol Oncol 1996; 18:36.
  3. Lazarin GA, Haque IS, Nazareth S, et al. An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals. Genet Med 2013; 15:178.
  4. Kingsmore S. Comprehensive carrier screening and molecular diagnostic testing for recessive childhood diseases. PLoS Curr 2012; :e4f9877ab8ffa9.
  5. National Human Genome Research Institute. DNA sequencing costs: Data from the NHGRI large-scale genome sequencing program. http://www.genome.gov/sequencingcosts (Accessed on August 09, 2017).
  6. Musci TJ, Caughey AB. Cost-effectiveness analysis of prenatal population-based fragile X carrier screening. Am J Obstet Gynecol 2005; 192:1905.
  7. Chokoshvili D, Vears DF, Borry P. Growing complexity of (expanded) carrier screening: Direct-to-consumer, physician-mediated, and clinic-based offers. Best Pract Res Clin Obstet Gynaecol 2017; 44:57.
  8. Committee on Genetics. Committee Opinion No. 690: Carrier Screening in the Age of Genomic Medicine. Obstet Gynecol 2017; 129:e35.
  9. Edwards JG, Feldman G, Goldberg J, et al. Expanded carrier screening in reproductive medicine-points to consider: a joint statement of the American College of Medical Genetics and Genomics, American College of Obstetricians and Gynecologists, National Society of Genetic Counselors, Perinatal Quality Foundation, and Society for Maternal-Fetal Medicine. Obstet Gynecol 2015; 125:653.
  10. Gross SJ, Pletcher BA, Monaghan KG, Professional Practice and Guidelines Committee. Carrier screening in individuals of Ashkenazi Jewish descent. Genet Med 2008; 10:54.
  11. Grody WW, Thompson BH, Gregg AR, et al. ACMG position statement on prenatal/preconception expanded carrier screening. Genet Med 2013; 15:482.
  12. Stevens B, Krstic N, Jones M, et al. Finding Middle Ground in Constructing a Clinically Useful Expanded Carrier Screening Panel. Obstet Gynecol 2017; 130:279.
  13. Committee on Genetics. Committee Opinion No. 693: Counseling About Genetic Testing and Communication of Genetic Test Results. Obstet Gynecol 2017; 129:e96.
  14. Committee on Genetics. Committee Opinion No. 691: Carrier Screening for Genetic Conditions. Obstet Gynecol 2017; 129:e41.
  15. Hoyert DL, Mathews TJ, Menacker F, et al. Annual summary of vital statistics: 2004. Pediatrics 2006; 117:168.
  16. Committee on Patient Safety and Quality Improvement, American College of Obstetricians and Gynecologists. Committee Opinion No.546: Tracking and reminder systems. Obstet Gynecol 2012; 120:1535.
  17. Ross LF, Saal HM, David KL, et al. Technical report: Ethical and policy issues in genetic testing and screening of children. Genet Med 2013; 15:234.